G1 Therapeutics sell kostojunior
Start price
25.06.24
/
0%
€1.94
Target price
25.06.25
-
Performance (%)
15.14%
End price
06.07.24
€2.24
Summary
This prediction ended on 06.07.24 with a price of €2.24. The prediction closed with a disappointing performance of 15.14%. This prediction was marked as speculative and is excluded from kostojunior's performance statistics.G1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w |
|---|---|
| G1 Therapeutics | 12.075% |
| iShares Core DAX® | 0.383% |
| iShares Nasdaq 100 | 1.543% |
| iShares Nikkei 225® | 2.596% |
| iShares S&P 500 | 0.573% |
According to kostojunior what are the pros and cons of G1 Therapeutics for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
High dividend yield expected
Cons
Bad rating
Lower EBIT Margin than peer group
Revenue decline/stagnation expected
Increased challenges to pay loans and raise capital
Comments by kostojunior for this prediction
In the thread G1 Therapeutics diskutieren
Sell G1 Therapeutics
In the thread Trading G1 Therapeutics
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.